Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results

Interpace Diagnostics (IDXG) Tops Q4 EPS by 73c, Revenues Miss; Offers 1Q Revenue Guidance Below Consensus, Withdraws FY20 Guidance

April 22, 2020 4:44 PM EDT

Interpace Diagnostics (NASDAQ: IDXG) reported Q4 EPS of ($0.01), $0.73 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $4.07 million versus the consensus estimate of $10.77 million.

Withdraws Full-Year 2020 Guidance

Fiscal 2019 was a transformational year for us as we... More